VEGFA and pseudoxanthoma elasticum (inherited or acquired): Since then, intravitreal anti-VEGF treatment has been the subject of multiple case reports, case series, and clinical trials and has emerged as the first-choice treatment for CNV secondary to angioid streaks and the ocular manifestations of PXE [68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88] (Table 1).